As of January 8 at 3:00:00 PM EST. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jun 2013) | Next Qtr. (Sep 2013) | Current Year (2013) | Next Year (2014) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -0.89 | -0.68 | -1.33 | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Jun 2013) | Next Qtr. (Sep 2013) | Current Year (2013) | Next Year (2014) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| Currency in USD | 6/30/2012 | 9/30/2012 | 12/31/2012 | 3/31/2013 |
|---|---|---|---|---|
| EPS Est. | -0.67 | -0.71 | -0.61 | -0.65 |
| EPS Actual | -0.89 | -0.68 | -0.63 | -0.9 |
| Difference | -0.22 | 0.03 | -0.02 | -0.24 |
| Surprise % | -32.84% | 4.49% | -3.21% | -37.25% |
EPS Trend
| Currency in USD | Current Qtr. (Jun 2013) | Next Qtr. (Sep 2013) | Current Year (2013) | Next Year (2014) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Jun 2013) | Next Qtr. (Sep 2013) | Current Year (2013) | Next Year (2014) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | 1 | -- |
| Up Last 30 Days | 1 | 1 | 1 | -- |
| Down Last 7 Days | -- | -- | -- | 1 |
| Down Last 30 Days | -- | -- | -- | 1 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| AFFY | -- | -- | -- | -- |
| S&P 500 | 8.70% | 11.55% | 14.03% | 13.42% |
Upgrades & Downgrades
| Downgrade | McNicoll Lewis Vlak: Sell | 3/19/2013 |
| Downgrade | Lazard: Buy to Neutral | 2/26/2013 |
| Downgrade | JMP Securities: Market Outperform to Market Underperform | 2/25/2013 |
| Downgrade | Piper Sandler: Overweight to Neutral | 2/25/2013 |
| Downgrade | Piper Sandler: Overweight to Neutral | 2/25/2013 |
| Downgrade | Stifel: Buy to Hold | 2/25/2013 |
Related Tickers
4593.T Healios K.K.
202.00
+4.66%
ATHXQ Athersys, Inc.
0.0000
0.00%
VXL.V Vaxil Bio Ltd.
0.0100
0.00%
NGNE Neurogene Inc.
19.75
-8.10%
SLGL Sol-Gel Technologies Ltd.
1.0712
-3.50%
CVM CEL-SCI Corporation
0.4000
+9.17%
ONCY Oncolytics Biotech Inc.
0.8533
-1.69%
MAIA MAIA Biotechnology, Inc.
2.0850
-2.12%
INCY Incyte Corporation
70.06
-4.20%
PLX Protalix BioTherapeutics, Inc.
2.2250
-1.98%